Dr. Jessica E. Maxwell, MBA, MD

Dr. Maxwell practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Maxwell's NPI, 1487949905, was assigned on June 13, 2011. Dr. Maxwell graduated from Carver College of Medicine in 2011. Dr. Maxwell holds Texas license R6242.

Dr. Maxwell's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Maxwell's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Maxwell practices. Vendor and product names are available with a free account.

Surgery is Dr. Maxwell's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Maxwell is board certified in complex general surgical oncology by the American Board of Surgery. Dmand AI has Dr. Maxwell's licenses on file in 11 states: Texas, Florida, Arizona, Georgia, Mississippi, Washington, Alabama, Louisiana, Oklahoma, Tennessee and Iowa.

Dmand AI lists abdominal adhesion surgery and colon removal among the conditions Dr. Maxwell treats.

CMS data shows 312 Medicare services from Dr. Maxwell across 5 procedure codes in 2024, for 218 Medicare patients. Medicare paid $24,416 for them.

CMS counts 218 Medicare patients who saw Dr. Maxwell in 2024. The largest group is 65 to 74, with 127 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Maxwell's median patient age at 71, with 47% women.

In 2024, Dr. Maxwell wrote 21 Medicare Part D claims. 100% of them were for generic drugs. CMS names the drug for 13 of them, across 1 drug with 11 or more claims each, at $10,899 in total drug cost. In 2019, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Maxwell for performance year 2024, reported as part of a group. Dr. Maxwell accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Maxwell as offering telehealth.

Dmand AI links 61 papers to Dr. Maxwell, published from 2011 to 2025. 2023 was the busiest year, with 9. The most frequent topics are Neuroendocrine Tumors, Pancreatic Neoplasms and Pancreatectomy. Dr. Maxwell has published most often in Ann Surg Oncol. Dr. Maxwell's most frequent co-authors are Ching-Wei David Tzeng, MD, Matthew Harold Katz, MD and Naruhiko Ikoma, MD.

CMS Open Payments shows 26 general payments to Dr. Maxwell from 10 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 60% of the total. Ipsen Biopharmaceuticals, Inc paid the most, $3,550.

Dr. Maxwell graduated from Carver College of Medicine in 2011.

Dr. Maxwell is in network with 4 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 3. Check the plan with the practice before a visit.